first in.
Dear Friends,

BrightFocus Foundation continues to grow as a premier source of funding and support for scientific research to defeat Alzheimer’s, glaucoma, and macular degeneration. Thanks to the generosity and support of friends like you, we are leading the fight against the devastating conditions we all fear most: loss of sight and loss of mind.

We make bold bets on the future, investing in groundbreaking science that will change lives. BrightFocus recently announced $13.3 million in new grants, a record amount that brings us to more than $36 million awarded in the past three years alone. In supporting cutting-edge research and investing in the next generation of bright young minds, we’re funding the future we want for our loved ones and ourselves.

As our nation and the world’s population ages, it is imperative that we change the trajectory of these diseases. Our research ranges from better understanding how our bodies age, to the clinical testing of promising new treatments. BrightFocus was the first to invest in an innovative statistical model to accelerate Alzheimer’s research, and the first to bring eye and brain researchers together to fuel new collaborations. The strong reputation of our research allows us to continue to reach larger audiences—sharing information with families impacted by these diseases and fostering partnerships with public and private sector leaders.

The diseases we take on are daunting, but we don’t fear being unable to find cures. We only fear that we won’t find them soon enough to help the ones we love. Working together, we won’t let this happen.

STACY PAGOS HALLER  SCOTT D. RODGVILLE, CPA
President and CEO  Chair, Board of Directors
BrightFocus is leading the fight against the devastating conditions we fear most: loss of sight and loss of mind.

BrightFocus Foundation’s three scientific research programs to end diseases of mind and sight are Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research.

Supporting Innovative Research

BrightFocus-supported research advances the work of scientists around the world.

Table of Contents

<table>
<thead>
<tr>
<th>Alzheimer’s Disease Research</th>
<th>Scientific Review Committees</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>13</td>
</tr>
<tr>
<td>Macular Degeneration Research</td>
<td>Partnerships For A Cure</td>
</tr>
<tr>
<td>6</td>
<td>15</td>
</tr>
<tr>
<td>National Glaucoma Research</td>
<td>Investing In A Cure</td>
</tr>
<tr>
<td>8</td>
<td>16</td>
</tr>
<tr>
<td>2017 Grant Recipients</td>
<td>Financial Highlights</td>
</tr>
<tr>
<td>10</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>Board &amp; Leadership</td>
</tr>
<tr>
<td></td>
<td>19</td>
</tr>
</tbody>
</table>
Alzheimer’s Disease Research

Every 66 seconds, another American develops Alzheimer’s disease, the sixth-leading cause of death in the United States and the only leading cause of death that has significantly increased in recent years. Alzheimer’s has no known cure.

Researcher Spotlight

To Understand the Aging Brain, Study the Young Brain

Stacy Grunke, PhD, a postdoctoral fellow at Baylor College of Medicine in Houston, studies Alzheimer’s disease because she’s “fascinated by the learning and memory circuitry of the brain, and the loss of cognitive function with aging.”

Grunke is examining how the young brain is able to restore cognitive function despite instances of profound cell loss. “We hope that by understanding how the young brain recovers, we can then identify which of these mechanisms is lost with age, with the hope of restoring cognitive function in the aged population,” she says.

“I think the most promising area of research is identifying genetic risk factors of the disease,” notes Grunke. She predicts: “As genetic screens become available to identify people likely to develop the disease and advances in brain scans enable confirmation of Alzheimer’s pathology, we will begin to see real improvements from early interventions that target the disease.”

Over 5 million people live with Alzheimer’s disease in the United States today, by 2050 there will be close to 15 million.
“Research equals hope. These young scientists represent the future.”

Frank M. LaFerla, PhD
University of California, Irvine

**Incubator for Rising Researchers**

BrightFocus sponsored its biennial conference, Alzheimer’s Fast Track, which serves as a boot camp for young scientists to hear from leading experts in the Alzheimer’s field. This signature event fosters unique collaboration among both seasoned and promising scientists.

Frank M. LaFerla, PhD, University of California, Irvine, a renowned Alzheimer’s investigator, said, “Research equals hope. There is no doubt about it. We are never going to find a cure for these diseases other than through research. These young scientists represent the future.”

**Crowdsourcing Public’s Help**

**EyesOnALZ**

Funded by BrightFocus, EyesOnALZ is the first-ever, citizen science project to engage the public with Alzheimer’s research. The project uses crowdsourcing to speed up time-consuming data analysis for research studying stalled blood vessels in the brain. Headed by Pietro Michelucci, PhD, of Ithaca, NY-based Human Computation Institute, EyesOnALZ was recently featured in a PBS documentary series, The Crowd & The Cloud.

**Fostering Dementia Friendly Communities**

As a founding member of Dementia Friendly America, BrightFocus has partnered with Montgomery County, Maryland, to launch a local campaign to better serve those in our community living with dementia.

$8.4m

BrightFocus has funded more than $8.4 million to 38 new projects
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in the United States, and for Caucasians older than 40 it is the leading cause of blindness. BrightFocus convened the first-ever international gathering of brain and eye researchers to map out an ambitious research agenda on the common features of neurodegenerative diseases.

Perhaps it’s no surprise that a scientist with an interdisciplinary background believes that interdisciplinary work will help solve the puzzle that is age-related macular degeneration (AMD).

Kaustabh Ghosh, PhD, of the University of California, Riverside, has a background in vascular biology, mechanobiology, and bioengineering, and was drawn to vision research by a colleague who encouraged him to explore AMD and diabetic retinopathy.

While these two vision conditions have long been known to involve vascular dysfunction, a topic that is of central interest in Dr. Ghosh’s lab, very little is known about precisely how blood vessels become dysfunctional or the extent to which vessel dysfunction affects vision.

Dr. Ghosh is studying the role of age-related vascular stiffening in the development of dry AMD, an approach that, if successful, could lead to new treatments for dry AMD.
“I really appreciate this program. I can’t tell you how much it means to me. I wouldn’t miss it for anything.”

Ella
A longtime chat listener
Wooster, Ohio

Tips for Families and Caregivers

The BrightFocus Chats, a monthly telephone call-in series featuring researchers, clinicians, and low vision specialists, provide the latest advice for those living with vision loss. All the chats are archived at brightfocus.org.

On a recent chat, Dr. Ward Bond, the host of a national television program, shared his expertise about the vital role of nutrition in reducing the risk and progression of age-related diseases such as macular degeneration and glaucoma.

BrightFocus Chats

$2.6m
BrightFocus has funded more than $2.6 million of 17 new projects

Above: Zhihong Hu, PhD
Left: From the lab of Aparna Lakkaraju, PhD

Rajendra Kumar-Singh, PhD
National Glaucoma Research

Glaucoma is the second leading cause of irreversible blindness worldwide according to the World Health Organization. And for Hispanics and African-Americans in the United States, glaucoma is the leading cause of blindness.

Through social media campaigns and public service announcements, BrightFocus works to educate Americans on the importance of scheduling a regular eye exam.

Researcher Spotlight

An Engineer’s Perspective

Darryl Overby, PhD, of the Department of Bioengineering at Imperial College, London, has been fascinated since college with biofluid mechanics. That’s the study of fluid motion in response to certain pressures or forces.

While engineers typically focus on fluid motion in pipes or plumbing, Overby became “captivated with how the same ideas can be applied to the human body, to understand disease.”

For years Overby has been investigating the fluid mechanics of the eye in glaucoma, looking at the mechanics of fluid drainage (the aqueous humour) in the eye. He believes the eye’s drainage pathway can be better targeted to more successfully lower intraocular pressure, which in turn can help prevent vision loss in glaucoma.

Overby is encouraged about the future of glaucoma research, seeing certain compounds progress from “bench to bedside” and begin to help patients.

“As we learn more about the trabecular meshwork and aqueous humour dynamics in general,” says Overby, “no doubt even better and more effective vision-saving drugs will emerge. Stay tuned!”

Only half of people living with glaucoma are likely aware they have it.
“I have light colored eyes and a thin cornea. Surgery to repair a macular pucker resulted in central vision loss. This loss just compounded the damage done to the same eye from advanced glaucoma. Protecting my eyes is paramount in preserving what eye sight I do have.”

Marilyn Pope

Twitter Chats Stats

#GlaucomaTalk – 700,000 impressions and 140,000 reach from Twitter Chat with Dr. Goldberg

$2.2m

BrightFocus has funded more than $2.2 million of 15 new projects

Clinical Trials Guide

BrightFocus recently released a new publication designed to help families seeking information on clinical trials for diseases of mind and sight.

Email info@brightfocus.org to receive a free copy of Clinical Trials: Your Questions Answered brochure or download it at brightfocus.org/clinical-trials.

From the lab of Matthew Van Hook, PhD
2017 BrightFocus Awards

These 70 new awards totaling more than $13 million contribute to a portfolio of more than $35 million with 177 awards managed during fiscal 2017.

2017 BrightFocus Grants at a Glance

**Basic** — Research that aims to better understand how a disease happens, and to obtain new ideas of how to stop the disease.

**Clinical** — Research involving volunteer participants to test the safety and effectiveness of drugs, devices, or other treatment candidates.

**Translational** — Research to move findings from the lab bench to the “bedside” by testing potential treatments.

<table>
<thead>
<tr>
<th>Grant Type</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Research Grants</td>
<td>47%</td>
</tr>
<tr>
<td>Clinical Research Grants</td>
<td>15%</td>
</tr>
<tr>
<td>Translational Research Grants</td>
<td>38%</td>
</tr>
</tbody>
</table>
Shahmaz Kemal, PhD
Unexplored Toxic Pathways in Alzheimer’s: Potential New Drug Targets
NORTHWESTERN UNIVERSITY

Chaeyoung Kim, PhD
ApoE4 and Mitochondrial Function in Alzheimer’s Disease
THE J. DAVID GLADSTONE INSTITUTES

Terrance Kummer, MD, PhD
An MRI Fingerprint of Brain Circuit Breakdown in Alzheimer’s
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

Tae Ho Lee, PhD
A New Pathway to Neuron Death in Alzheimer’s Disease
BETH ISRAEL DEACONESS MEDICAL CENTER, HARVARD MEDICAL SCHOOL

Jin Rui Liang, PhD
Link Between Endoplasmic Reticulum Turnover & Neurodegeneration in Alzheimer’s
UNIVERSITY OF CALIFORNIA, BERKELEY

Ethan Lippman, PhD
Why Do Brain Blood Vessels Become Leaky in Alzheimer’s and Dementia?
VANDERBILT UNIVERSITY

Tao Ma, MD, PhD
A Potential New Drug Target to Prevent Alzheimer’s-related Synapse Loss
WAKE FOREST UNIVERSITY MEDICAL SCHOOL

Edoardo Marcara, PhD
Understanding the Role of Apolipoprotein E in Microglia
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Randy McIntosh, PhD
Building a Personalized Virtual Brain with Alzheimer’s
BAYCREST CENTRE FOR GERIATRIC CARE

Myles Minter, PhD
This Alzheimer’s Disease Research Fellowship Grant is made possible in part by support from Lois and Duane Luallin in Memory of Denver E. Perkins and Edwin H. Luallin.
This grant is made possible by support from the Nancy Ferguson Seeley Trust in memory of Mildred F. Ferguson

Yi Su, PhD
Neurovascular Changes in Aging and Alzheimer Disease
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

Peter Tessier, PhD
New Tau Imaging for Early Diagnosis of Alzheimer’s
UNIVERSITY OF MICHIGAN

Robert Newton, PhD
Exercise to Reduce Alzheimer’s Risk in African Americans
PENNINGTON BIOMEDICAL RESEARCH CENTER

Daniel Pak, PhD
Testing a Novel Amyloid-Promoting Factor as an Alzheimer’s Therapy
GEORGETOWN UNIVERSITY

Angèle Parent, PhD
Targeting APP Intracellular Fragment to Improve Memory and Reduce Aβ Burden in AD
UNIVERSITY OF CHICAGO

Chris Schaffer, PhD
Improving Brain Blood Flow in Alzheimer’s Disease to Improve Cognitive Function
CORNELL UNIVERSITY

Yong Wang, PhD
A New Way to Image White Matter Damage and Inflammation in Alzheimer’s
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

Daniel Chao, MD, PhD
A Zebrafish Model of Wet Macular Degeneration
UNIVERSITY OF CALIFORNIA, SAN DIEGO

Jing Chen, PhD
Protecting RPE and Photoreceptors in AMD
CHILDREN’S HOSPITAL BOSTON, HARVARD MEDICAL SCHOOL

Yan Chen, PhD
Metabolic Pathways of the Retina in Health and AMD
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON

Astra Dinculescu, PhD
Extracellular Deposits and Vision Loss in AMD
UNIVERSITY OF FLORIDA

Cristhian Ildefonso, PhD
The Helen Juanita Reed Award
Exploring the Role of Inflammation in AMD
UNIVERSITY OF FLORIDA

Rajendra Kumar-Singh, PhD
Developing a Gene Therapy for AMD
TUFTS UNIVERSITY

Binxing Li, PhD
Delivering Sight-saving Nutrients to the Retina in AMD
MORAN EYE CENTER

Sarah McFarlane, PhD
Aberrant Blood Vessel Growth in AMD: A New Animal Model
UNIVERSITY OF CALGARY

Trevor McGill, PhD
The Carolyn K. McGillvray Award
Nutritional Factors in the Development of AMD
OREGON HEALTH AND SCIENCE UNIVERSITY

Philippe Mourrain, PhD
This grant is made possible by support from the Nancy Ferguson Seeley Trust in memory of Mildred F. Ferguson
Can the Zebrafish Provide Clues to New AMD-Associated Genetic Mutation?
STANFORD UNIVERSITY

Patsy Nishina, PhD
Which DNA Changes Can Lead to AMD and Other Vision Disease?
THE JACKSON LABORATORY

Michael Paulaitis, PhD
MicroRNAs and Mitochondrial Dysfunction in AMD
JOHNS HOPKINS UNIVERSITY
Claudio Punzo, PhD
Role of the Light-sensing Photoreceptor Cells in AMD
UNIVERSITY OF MASSACHUSETTS SCHOOL OF MEDICINE

Sheldon Rowan, PhD
The Elizabeth Anderson Award
Importance of Gut Bacteria in A Model of AMD
TUFTS UNIVERSITY

Daniel Saban, PhD
Targeting Immune Cells in AMD
DUKE UNIVERSITY EYE CENTER

Gaofeng Wang, PhD
Using Vitamin C to Treat AMD
UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE

Brad Fortune, OD, PhD
The Thomas R. Lee Award
Can Imaging Reveal Early Stage Damage to Individual Optic Nerve Fibers
DEVERS EYE INSTITUTE

Esther Gonzalez, PhD
Testing the Brain Structure Connecting Two Hemispheres in Glaucoma
KREMBIL RESEARCH INSTITUTE

Douglas Gould, PhD
Growth Factor Signaling in Eye Development
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Krish Kizhatil, PhD
Neuronal Control of IOP
THE JACKSON LABORATORY

Andras Komaromy, DVM, PhD
A Gene Therapy Approach to Neuroprotection in Glaucoma
MICHIGAN STATE UNIVERSITY

Weiming Mao, PhD
CRISPR Interference for Glaucoma
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER

Ethan Rossi, PhD
Imaging the Cells Affected by Glaucoma in the Human Eye
UNIVERSITY OF PITTSBURGH

Feliks (Ephraim) Trakhtenberg, PhD
New Approach for Regenerating the Injured Optic Nerve
UNIVERSITY OF CONNECTICUT MEDICAL CENTER

Matthew Van Hook, PhD
Effects of Elevated IOP on Ganglion-Cell Photoreceptors
UNIVERSITY OF NEBRASKA MEDICAL CENTER

Derek Welsbie, MD, PhD
The Dr. Douglas H. Johnson Award
Gene Therapy to Inhibit Retinal Nerve Cell Death in Glaucoma
UNIVERSITY OF CALIFORNIA, SAN DIEGO

Ji Yi, PhD
A New Imaging Technique to Detect Early Markers of Glaucoma
UNIVERSITY OF CALIFORNIA, SAN DIEGO

Andras Komaromy, DVM, PhD
A Gene Therapy Approach to Neuroprotection in Glaucoma
MICHIGAN STATE UNIVERSITY

Weiming Mao, PhD
CRISPR Interference for Glaucoma
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER

Ethan Rossi, PhD
Imaging the Cells Affected by Glaucoma in the Human Eye
UNIVERSITY OF PITTSBURGH

Gulab Zode, PhD
Novel Treatment for Steroid and Myocilin Glaucoma
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER

Special Thanks to Donors Supporting Ongoing Research

ALZHEIMER'S DISEASE RESEARCH

Jean-Vianney Haure-Mirande, PhD
This grant is made possible by support from the J.T. Tai Foundation.
Role of Microglia in Alzheimer's Disease: Deleterious or Helpful?
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

David Irwin, MD
Non-Amnestic Alzheimer's Disease Biology
UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE

Ana Pereira, MD
Enhancing Glutamate Levels as a Way to Treat Alzheimer's Disease
THE ROCKEFELLER UNIVERSITY

Paul Seidler, PhD
This grant is made possible in part by support from Alzheimer's Greater Los Angeles.
Blocking Assembly of Tau Protein into Toxic Structures Associated with Alzheimer's Disease
UNIVERSITY OF CALIFORNIA, LOS ANGELES

MACULAR DEGENERATION RESEARCH

Jeffrey L. Goldberg, MD, PhD
This clinical trial is made possible in part by support from The Barry Friedberg & Charlotte Moss Family Foundation.
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
STANFORD UNIVERSITY

National Glaucoma Research
Our world-class scientific review committees, featuring renowned scientific leaders, recommend the annual BrightFocus research grants with the goal of discovering a treatment or cure of Alzheimer’s, macular degeneration, and glaucoma.

BrightFocus Scientific Review Committees

Co-Chair:
David R. Borchelt, PhD
University of Florida

Co-Chair:
David M. Holtzman, MD
Washington University School of Medicine

Committee Members:
Beau Ances, MD, PhD, MSc
Washington University School of Medicine

M. Flint Beal, PhD
The New York Hospital – Cornell Medical Center

Mark D’Esposito, MD
University of California, Berkeley

Guojun Bu, PhD
Mayo Clinic, Jacksonville

George Carlson, PhD
McLaughlin Research Institute

Steven Estus, PhD
University of Kentucky

Matthew Frosch, MD, PhD
Massachusetts General Hospital

Douglas Galasko, MD
University of California, San Diego

Yukiko Goda, PhD
RIKEN Brain Science Institute (Japan)

Charles G. Glabe, PhD
University of California, Irvine

Alison M. Goate, DPhil
Icahn School of Medicine at Mount Sinai

Todd E. Golde, MD, PhD
University of Florida

John Hardy, PhD, FMedSci, FRS
University College London

Julie Harris, PhD
Allen Institute for Brain Science

John “Keoni” Kauwe, PhD
Brigham Young University

Allan I. Levey, MD, PhD
Emory University

Edward Koo, MD
University of California, San Diego

Cynthia Lemere, PhD
Harvard Medical School, Brigham and Women’s Hospital

Ronald K. Liem, PhD
Columbia University

Hendrik Luesch, PhD
University of Florida

John M. Olichney, MD
University of California, Davis

David P. Salmon, PhD
University of California, San Diego

Gerard Schellenberg, PhD
University of Pennsylvania School of Medicine

Jane M. Sullivan, PhD
University of Washington School of Medicine

David B. Teplow, PhD
University of California, Los Angeles

Gopal Thinakaran, PhD
University of Chicago

Ronald B. Wetzl, PhD
University of Pittsburgh

Tony Wyss-Coray, PhD
Stanford University Medical School

BrightFocus grantees have received numerous prestigious awards including two Nobel Prizes, 49 Met Life Foundation Awards and 34 Potamkin Prizes.
Kristine Yaffe, MD
University of California, San Francisco

Riqiang Yan, PhD
Cleveland Clinic Foundation

Hui Zheng, PhD
Baylor College of Medicine

Chair:
Joe G. Hollyfield, PhD
The Cleveland Clinic Foundation

Committee Members:
Bela Anand-Apte, PhD
The Cleveland Clinic Foundation

Robert E. Anderson, MD, PhD
University of Oklahoma Health Sciences

John D. Ash, PhD
University of Florida

Alan Bird, MD
University College London

Dean Bok, PhD
University of California, Los Angeles

Catherine Bowes-Rickman, PhD
Duke University

Deborah Ferrington, PhD
University of Minnesota

Steven Fliesler, PhD
SUNY, Buffalo

Claire Harris, PhD
Cardiff University (Wales)

Alfred S. Lewin, PhD
University of Florida

Michael B. Gorin, MD, PhD
University of California, Los Angeles

John Penn, PhD
Vanderbilt University School of Medicine

Nancy J. Philp, PhD
Thomas Jefferson University

Sylvia B. Smith, PhD
Augusta University

Debra Thompson, PhD
University of Michigan

Adriana Di Polo, PhD
University of Montreal (Canada)

C. Ross Ethier, PhD
Georgia Institute of Technology and Emory School of Medicine

Thomas F. Freddo, OD, PhD
University of Waterloo (Canada)

Jeffrey L. Goldberg, MD, PhD
Stanford University

Richard Libby, PhD
University of Rochester Medical Center

Nicholas Marsh-Armstrong, PhD
Johns Hopkins University

Stuart J. McKinnon, MD, PhD
Duke University

Robert W. Nickells, PhD
University of Wisconsin

Ian A. Sigal, PhD
University of Pittsburgh School of Medicine

Arthur J. Sit, MD
Mayo Clinic, MN

W. Daniel Stamer, PhD
Duke University

James N. Ver Hoeve, PhD
University of Wisconsin

Monica Vetter, PhD
University of Utah

Darrell WuDunn, MD, PhD
Indiana University

Mary Wirtz, PhD
Oregon Health & Science University

Chair:
John C. Morrison, MD
Oregon Health & Science University

Committee Members:
R. Rand Allingham, MD
Duke University

Claude Burgoyne, MD
Devers Eye Institute

Abbot F. Clark, PhD
University of North Texas

Anne Coleman, MD, PhD
University of California, Los Angeles

National Glaucoma Research

Macular Degeneration Research

Left image credit:
Marie-Victoire Guillot-Setstier, PhD

Right image credit:
Tracy Young-Pearse, PhD
Partnerships For A Cure

BrightFocus works closely with nonprofits and corporate partners alike to advocate for those impacted by loss of mind and loss of sight. We collaborate with leading coalitions, key policymakers and elected officials to seek greater allocation of federal resources and support for caregivers.

Global Network for Alzheimer’s

BrightFocus partners with four European countries to advance research and provide public awareness of Alzheimer’s disease.

Belgium
Stichting Alzheimer Onderzoek

France
La Fondation Vaincre Alzheimer

Germany
Alzheimer Forschung Initiative e.V.

The Netherlands
Internationale Stichting Alzheimer Nederland
Investing In A Cure

On behalf of current and future generations who benefit from the research funded by Alzheimer’s Disease Research, Macular Degeneration Research and National Glaucoma Research, BrightFocus thanks our generous donors for funding the future we want for our loved ones and ourselves.

We are so fortunate to be supported by many individuals, private foundations and corporations for our programs that advance research and promote public awareness on loss of mind and loss of sight.

A wide range of contribution opportunities is available to accommodate resources and charitable goals. Each gift is important and needed to help us find a cure.

An Evening of BrightFocus

Our second annual dinner in Washington brought together nearly 300 leaders from business, science, and government to celebrate excellence in research and advocacy. Seven BrightFocus-funded scientists shared their current project highlights and their hopes for the future.

Sowing the Seeds of Scientific Progress

BrightFocus-funded researchers often go on to receive awards TEN TIMES GREATER from NIH and other sources, a 1,000% return on our early investment.

Above: J. Crawford Downs, PhD, University of Alabama at Birmingham

Right: Joe G. Hollyfield, PhD, Cleveland Clinic; Stacy Haller, BrightFocus; Jennifer Gatchel, MD, PhD, Harvard Medical School; George Vradenburg, USAgainstAlzheimer’s

Left: Meryl Comer, Geoffrey Beene Alzheimer’s Initiative; Kim Campbell, Careliving.org

Right: Keith Carradine, entertainer;
Donor Spotlight

Many BrightFocus donors have special connections to the research programs they support. We are honored to share two of those stories with you.

Optimism and Hope about Alzheimer’s Disease Research

Joanne Strate’s enthusiasm and love of life are obvious as she shares how she came to support planned giving for Alzheimer’s Disease Research (ADR).

Ms. Strate, an active retiree from Minnesota, is motivated to support science because of her mother who died in 2012, seven years after an Alzheimer’s diagnosis.

She is passionate about the need for more financial support of Alzheimer’s research. “It’s a no-brainer for me, especially with no children or spouse, to designate 20 percent of my estate for research.” Gifts such as hers to ADR help support scientists worldwide, as they work to end the disease.

“I feel hopeful that science is getting closer to slowing the growth of Alzheimer’s and understanding it all,” she says.

Sharing a Mission on Vision Health

For more than 80 years, the Service for Sight program has been the hallmark of Delta Gamma, a national sorority. In 1936, Delta Gamma initiated an international philanthropy resulting from the plea of a young alumna, Ruth Billow, who was blind and encouraged the group to support a “talking book” as a project to aid the blind.

The Delta Gamma Foundation’s Service for Sight has grown into a program that every year positively impacts more than one million children and adults who are blind or visually impaired.

“We are committed to supporting national organizations that share the Delta Gamma Foundation’s mission,” said Kate Morales, a program specialist with the Delta Gamma Foundation. “We feel that if Ruth was with us today, she would be inspired by the impactful work of BrightFocus, and their Chat tele-forum series to help individuals interested in learning more about vision health.”

Above left: Joanne Strate, center, cites her mother Lillian, right, who had Alzheimer’s, as a major reason she supports Alzheimer’s Disease Research.

To right: Carol Dalton, a Delta Gamma member and volunteer at the Foundation for Blind Children in Phoenix, reads to a young boy who is vision impaired. On her shirt is a Delta Gamma motto: “do good.”
Financial Highlights

BrightFocus is a nonprofit organization designated under Section 501(c)(3) of the Internal Revenue Code. All contributions to BrightFocus and its programs are tax-deductible to the extent allowed by law. The Foundation is supported entirely by voluntary private contributions.

*BrightFocus received in-kind donations to expand public health information outreach and these are included in Program Services expenses. This allowed the organization to reach millions of people with information about risk factors, treatments and caregiving.

A complete copy of the financial statement audited by Raffa, P.C., is available upon request from BrightFocus at 1-800-437-2423 or www.brightfocus.org.

Consolidated Statement of Financial Position
As of March 31, 2017 (in thousands of dollars)

<table>
<thead>
<tr>
<th>Assets</th>
<th>$50,937</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Investments</td>
<td>$35,784</td>
</tr>
<tr>
<td>Charitable Trusts and Bequests Receivable</td>
<td>5,512</td>
</tr>
<tr>
<td>Rental Property</td>
<td>3,886</td>
</tr>
<tr>
<td>Fixed Assets, Net</td>
<td>4,513</td>
</tr>
<tr>
<td>Other Assets</td>
<td>1,242</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
</tr>
<tr>
<td>Accounts Payable and Other Liabilities</td>
<td>$545</td>
</tr>
<tr>
<td>Grants Payable</td>
<td>17,420</td>
</tr>
<tr>
<td>Charitable Gift Annuities</td>
<td>1,277</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>$19,242</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>$18,012</td>
</tr>
<tr>
<td>Temporarily Restricted</td>
<td>13,593</td>
</tr>
<tr>
<td>Permanently Restricted</td>
<td>90</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td>$31,695</td>
</tr>
</tbody>
</table>

Consolidated Statement of Activities
For the Fiscal Year Ended March 31, 2017 (in thousands of dollars)

<table>
<thead>
<tr>
<th>Support &amp; Revenue</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and Grants</td>
<td>$24,313</td>
</tr>
<tr>
<td>Bequests</td>
<td>6,250</td>
</tr>
<tr>
<td>Donated Services</td>
<td>15,795</td>
</tr>
<tr>
<td>Investment Income</td>
<td>2,883</td>
</tr>
<tr>
<td>Rental &amp; Other Income</td>
<td>797</td>
</tr>
<tr>
<td><strong>Total Support &amp; Revenue</strong></td>
<td>$50,038</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Programs* Research and Health Information Services</td>
<td>6% Management</td>
</tr>
<tr>
<td>Management and General</td>
<td>13% Fundraising</td>
</tr>
<tr>
<td>Fundraising</td>
<td>81%</td>
</tr>
<tr>
<td>Research</td>
<td>$16,888</td>
</tr>
<tr>
<td>Health Information Services</td>
<td>23,016</td>
</tr>
<tr>
<td><strong>Total Program Expenses</strong></td>
<td>$39,904</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Supporting Services</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>$6,339</td>
</tr>
<tr>
<td>Management and General</td>
<td>2,883</td>
</tr>
<tr>
<td><strong>Total Supporting Services</strong></td>
<td>$9,259</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$49,203</td>
</tr>
</tbody>
</table>

| Change in Net Assets             | $835    |
Leadership

BrightFocus Board of Directors

Chair
Scott D. Rodgville, CPA
Gorfine, Schiller & Gardyn, PA
Owings Mills, MD

Vice Chair
Diane I. Marcello
Sunriside Health Services
Sarasota, FL

Treasurer
Nicholas W. Raymond
USA (Ret.)
M&T Bank, retired
Silver Spring, MD

Secretary
Judith Lee
J. P. Morgan & Co., Inc.,
retired
Nantucket, MA

Michael H. Barnett, Esq.
Lieber & Associates, LLC
New York, NY

Maddy Dycktwald
Age Wave
San Francisco, CA

Grace Frisone
J. P. Morgan & Co., Inc., retired
Saratoga Springs, NY

June Kinoshita
Facioscapulohumeral Muscular Dystrophy Society
Waltham, MA

Patricia McGlothlin Stewart, CFP
J.P. Morgan & Co., Inc., retired
New York, NY

Henry J. Pownall, PhD
Houston Methodist Research Institute
Houston, TX

Brian K. Regan, PhD
New York-Presbyterian Hospital and Healthcare System
New York, NY

Ed Schoonveld
ZS Associates
New York, NY

Jan M. Stouffer, PhD
DuPont Company, retired
Parkersburg, WV

Ethan Treese
Nuix
Herndon, VA

Paul A. Greengard, PhD
Nobel Laureate
New York, NY

Stanley B. Prusiner, MD
Nobel Laureate
San Francisco, CA

Honorary Members

Our Senior Management Team

PRESIDENT & CEO
Stacy Pagos Haller

VICE PRESIDENT, SCIENTIFIC AFFAIRS
Diane Bovenkamp, PhD

VICE PRESIDENT, PUBLIC AFFAIRS
Michael Buckley

SENIOR VICE PRESIDENT, DEVELOPMENT
R. Brian Elderton

SENIOR VICE PRESIDENT, STRATEGIC PARTNERSHIPS
Nancy Lynn

VICE PRESIDENT, FINANCE AND ADMINISTRATION
David F. Marks, CPA, CMA
Our Mission
BrightFocus drives innovative research worldwide and promotes awareness of Alzheimer’s, macular degeneration, and glaucoma.

Programs
Alzheimer’s Disease Research
Macular Degeneration Research
National Glaucoma Research

Contact
22512 Gateway Center Drive
Clarksburg, MD 20871
1-800-437-2423

Integrity

Connect
www.brightfocus.org

Copyright © 2017 BrightFocus Foundation